Free-text search
Articles per year:
Content Types
-
Artisan Partners demands board changes at Novartis after share-price plunge
Artisan Partners, one of Novartis’ 20 largest shareholders, is demanding changes to the pharmaceutical company’s board and tighter oversight of acquisitions after two setbacks in clinical trials. Reuters reports this.
-
Breakthroughs in narcolepsy recognized by Lasker Awards
This year’s Lasker Awards are presented to researchers behind discoveries that have led to breakthroughs in narcolepsy and hemophilia – and to one of Hollywood’s most prominent patient activists.
-
Novonesis to invest €600 million in India factory
Danish biosolutions manufacturer Novonesis has decided to invest massively in its Indian factory.
-
Sobi gains regulatory momentum with new FDA Fast Track designation
Sobi has secured a US FDA Fast Track designation for pacritinib, advancing the drug’s development as a potential treatment for the rare and severe autoinflammatory disorder VEXAS syndrome.
-
AddLife adds new company to its portfolio
The Swedish life science group AddLife has acquired Unicam Sistemas Analíticos, a Portuguese distributor of advanced analytical laboratory equipment.
-
Denmark a leader in EU clinical trials: “We should never accept unnecessary delays”
A principal of quick processing as well as engaging in ongoing dialogue with sponsors has helped Denmark to lead EU in clinical trials.
-
Elizabeth Schepke named Childhood cancer researcher of the Year 2026
Oncologist Elizabeth Schepke has been named Childhood Cancer Researcher of the Year 2026 by the Swedish Childhood Cancer Foundation.
-
Bangladesh was close to eliminating measles – now it has the world’s largest outbreak
Bangladesh was close to eliminating measles. Now the country is battling the world’s largest outbreak, with more than 166,000 suspected cases and nearly 1,000 reported measles-related deaths since the spring.
-
SmartCella secures key patents in the US and Japan
Swedish drug-delivery company SmartCella has secured the main patent for its Extroducer device in the US and Japan, completing global protection following the European approval granted in 2024.
-
Regulatory milestone strengthens Xinnate’s EB program
Xinnate has received a notification from the U.S. Food and Drug Administration (FDA) that may bring significant advantages in the development of the company’s treatment for the skin disease Epidermolysis Bullosa (EB).
-
Nordic newcomer on an acquisition drive – snaps up four Swedish distributors
Over the past five years, Medu Group has built a Nordic distribution business. “We aim to become one of the major Nordic distributors in medtech,” says Magnus Schüldt, CEO of Medu Sverige.
-
Novo Nordisk Pharmatech CEO to step down
Ulla Grove Krogsgaard Thomsen has decided to leave Novo Nordisk Pharmatech to pursue af different career.
-
Novartis hit by another major setback – shares plunge
Novartis has suffered another major pipeline setback. A key drug candidate acquired through its $12bn takeover of Avidity has failed in phase III, sending the company’s shares down around 10 per cent.
-
BII injects fresh millions into six ‘promising’ Danish startups
BioInnovation Institute (BII) is allocating new convertible loans of EUR 1.3 million to six Danish startups previously backed by the organisation.
-
Political consensus on how to bring more new medicines to Sweden
Sweden is losing ground when it comes to access to new medicines. Ahead of the election, the country’s parliamentary parties are unusually united on what needs to change. Now, pharmaceutical industry association Lif is calling for that consensus to be turned into action.
-
Novo Nordisk halts two more heart drug trials
Novo Nordisk is discontinuing two Phase III trials of its drug candidate ziltivekimab in heart failure and inflammation.
-
Four in ten children shed obesity in Novo trial
A phase III study testing semaglutide in children with obesity met its primary endpoint, Novo Nordisk reports.
-
“Not the results we hoped for” – Novartis’ heart study shows no benefit
Novartis’ drug candidate pelacarsen, aimed at a well‑known cardiovascular risk factor, failed to reduce the risk of heart attack, stroke and cardiovascular death in a large Phase III trial.
-
FDA Breakthrough Device Designation lifts Neola shares
Lund-based Neola Medical has been granted the FDA’s Breakthrough Device Designation for Neola, the company’s medical device for continuous lung monitoring in preterm born babies.
-
Astra Zeneca receives US approval for Etcamah
The pharmaceutical company Astra Zeneca has received accelerated FDA approval for Etcamah in combination with a CDK4/6 inhibitor for advanced HR-positive, HER2-negative breast cancer with an ESR1 mutation.
-
Dialysis company hit with $15M bill after massive patient data breach
A cyberattack last year exposed the personal data of millions of patients at dialysis provider DaVita. Now the bill has arrived for the company: 15 million dollars in damages.
-
Sweden takes new steps to tackle oestrogen shortages
Sweden has struggled with shortages of oestrogen medicines for years, forcing women going through the menopause to switch products or search from pharmacy to pharmacy. Now, new measures aim to make it easier for healthcare professionals to find alternatives – including medicines not marketed in Sweden.
-
Lithuania accelerates life science ambitions with major cell therapy investment
A new center for cell therapy and personalized medicines has opened in the Lithuanian capital, Vilnius.
-
BII and GU Ventures collaborate on oligonucleotide project
Denmark’s BioInnovation Institute (BII) and Sweden’s GU Ventures are collaborating through a new cross-border project focused on therapeutic oligonucleotides.
BREAKING